Phase 1 Trial of Intraperitoneal AD-32 in Gynecologic Malignancies

Markman, Maurie; Homesley, Howard D.; Norberts, D.Andra; Schink, Julian C.; Abbas, Fouad; Miller, Antonius A.; Soper, John T.; Teng, Nelson N.H.; Hammond, Neel; Fm, Muggia; Israel, Mervyn; Sweatman, Trevor W.

doi:10.1006/gyno.1996.0102

Cited by 7 publications

(3 citation statements)

References 1 publication

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After initial studies assessing the safety and efficacy of its intraperitoneal administration in patients with advanced gynecologic malignancies (Markman et al, 1996), valrubicin has been approved in the United States for the topical treatment of bladder cancer in patients who fail standard therapy with intravesical bacillus Calmette-Guerin and are not eligible for radical surgery (Kuznetsov et al, 2001). Valrubicin is also considered as first-line medical therapy for superficial bladder cancer (van der Heijden and Witjes, 2003).…”

mentioning

confidence: 99%

Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

et al. 2004

View full text Add to dashboard Cite

mentioning

confidence: 99%

Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

et al. 2004

View full text Add to dashboard Cite

“…Valrubicin was reported to be safe in a phase I trial with advanced gynecological malignancies [203] and has thereafter …”

Section: Effects On Cell Proliferationmentioning

confidence: 99%

Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates

Gennäs

Talman²,

Yli‐Kauhaluoma³

et al. 2011

CTMC

View full text Add to dashboard Cite

Protein kinase C (PKC) comprises a family of ten isoforms that play roles in diverse cellular processes such as proliferation, apoptosis and differentiation. PKC isoforms respond to Gprotein coupled receptor-and receptor tyrosine kinase-signaling via binding the second messenger diacylglycerol with C1 domains. Aberrant signaling through PKC isoforms and other C1 domain-containing proteins has been implicated in several pathological disorders.Drug discovery concerning C1 domains has exploited natural products and rationally designed compounds. Currently, molecules from several classes of C1 domain-binding compounds are in clinical trials; however, still more have the potential to enter the drug development pipeline. This review gives a summary of the recent developments in C1 domain-binding compounds.

show abstract

“…Although bacterial peritonitis is a frequent complication of peritoneal dialysis, several cases of so-called “sterile” peritonitis have been described. These events can be caused not only by physical/chemical characteristics of the infused fluid, but also by drugs such as amphotericin B when added to peritoneal solutions to treat fungal peritonitis, or by antineoplastic agents when utilized intraperitoneally to treat abdominal cancers (1). To our knowledge, however, peritoneal inflammation has not yet been described in patients in whom antineoplastic agents are administered intravenously (IV).…”

mentioning

confidence: 99%